1190PDPhase II study of olaparib + durvalumab (MEDIOLA):...

Annals of Oncology 2019 / 10 Vol. 30; Iss. Supplement

1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Drew, Y, Kaufman, B, Banerjee, S, Lortholary, A, Hong, S H, Park, Y H, Zimmermann, S, Roxburgh, P, Ferguson, M, Alvarez, R H, Domchek, S, Gresty, C, Angell, H K, Ros, V Rocher, Meyer, K, Lanasa, M, He
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz253.016
Date:
October, 2019
File:
PDF, 91 KB
2019
Conversion to is in progress
Conversion to is failed